BRAF and melanoma: Finally, we run IMPACT-modules on a CRISPR-Cas9 knockout screen in the human melanoma cell line A375 [52], where the authors investigated the effect of gene loss upon treatment with vemurafenib, a therapeutic drug inhibitor of BRAF, by measuring cell viability in 4 different conditions (vehicle versus drug, 7 and 14 days).